INM News and Press, InMed Pharmaceuticals Inc. From 02/17/23

Closed calendar year 2022 with strong cash position of $11.5 million Approaches completion of enrollment for Ph 2 clinical trial in EB Advances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and ...

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we streng...

Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023 Progress preclinical research in glaucoma in preparation for human trials Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! Moving stocks this morning are a reverse stock split, ...

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The annou...

InMed Pharmaceuticals (( NASDAQ: INM ) IMLFF) has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services, pursuant to which, Mr. Jonathan Tegge, a member of Brio, will assume the role of interim CFO for the compan...

VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM ...